West Virginia’s First Allocation of Pfizer's COVID Vaccine Expected Dec. 14

West Virginia is gearing up to distribute its first allocations of coronavirus vaccines in the coming weeks.

Gov. Jim Justice said Wednesday that West Virginia’s initial allocation of Pfizer’s vaccine is expected to make its way to the state on Dec. 14. He said another vaccine developed by Moderna should follow in the days after.

Both companies filed applications this week for emergency use authorization with the Federal Drug Administration. The commissioner of the FDA said the agency is working “day and night” on the approvals.

With nearly half of the state’s coronavirus deaths attributed to nursing home patients and others in assisted living, Gen. James Hoyer of the West Virginia National Guard said doses of the vaccine will be delivered directly to those facilities.

State health officials have released a draft plan for distributing the vaccine. It prioritizes health care workers and those 65 years of age and older, as well as others at risk for severe illness from COVID-19.

W.Va Governor Talks Pfizer Vaccine, Sports As COVID Numbers Worsen

West Virginia is up to 530 reported deaths related to COVID-19. And there are more than 660 new cases of the virus in West Virginia since Sunday.

Gov. Jim Justice gave a grim update in his latest virtual press briefing Monday — 17 more deaths related to COVID-19 reported since Friday, and 27 additional deaths that occurred several weeks ago, according to the West Virginia Department of Health and Human Resources.

DHHR blamed local county health departments and hospitals for not immediately reporting the deaths, imploring local agencies to respond sooner.

With more than 6,900 active cases of the virus as of Monday night — up by 800 since Friday, state officials are being pressed to decide if current guidelines are adequately protecting the public.

Dr. Ayne Amjad, West Virginia’s state health officer, said it’s up to individuals to adhere to guidelines such as wearing masks, social distancing, and getting tested frequently.

“People need to have their lifestyle, their businesses open,” Amjad said. “We do hear people, what they’re saying; we hear the criticism, we take things into account. But life is not ‘stop-and-go,’ as the governor has mentioned multiple times, that life needs to go on.”

Amjad and other state officials stood by the state’s two color-coded maps, one that is updated daily by DHHR and the other that determines which county schools will be open for in-person school each week, and continued to implore West Virginians to get tested often for COVID-19.

This weekend also kicks off West Virginia’s high school football playoffs. The West Virginia Secondary School Activities Commission (WVSSAC) announced official team pairings over the weekend. However, whether teams will get to play will be determined Saturday evening when the latest education map drops.

Any county colored red or orange must forfeit.

“Sports are important, but they absolutely have to be laid to the sidelines just a little bit,” Justice said. “Sports are important. I’m a coach. I get it. But school’s more important. And surely to goodness, if we can’t go to school, we don’t need to be playing. In addition to all that, what is way more important than anything is to try to find a way to keep people from dying.”

The governor, while urging school sports personnel and student athletes to be cautious and follow health guidelines, made no efforts to push any additional restrictions on schools, school sports, or the state as a whole.

In college sports, 17 student athletes at Shepherd University last week tested positive for COVID-19. Shepherd has been administering surveillance testing of employees and students each Monday since Oct. 12. This testing is funded by the governor for all West Virginia’s public two-year and four-year higher education institutions.

The governor shared a bit of bright news, however, on a possible vaccine for the coronavirus. Pfizer announced Monday its experimental COVID-19 vaccine appears to be working — by more than 90 percent.

“This could be the biggest announcement that we have had in our lifetimes,” Justice said. “It is unbelievable to think that we have pulled that off. Pfizer has pulled that off in the timespan that has been out there to make that a reality.”

Justice said he believes, if all goes well with the final trials of the vaccine, it would be available to the most vulnerable and first responders by the end of November or December. He notes, however, it would be “months” before it would be distributed to the general population.

Mylan, Pfizer Subsidiary Strike Deal to Create New Pharmaceutical Company

This is a developing story and may be updated.

Mylan Pharmaceuticals and a division of Pfizer have announced a deal that will create a new pharmaceutical company expected to bring in $19 billion-$20 billion in annual revenue. 

According to a news release, Mylan and Upjohn, the Pfizer subsidiary, hosted a Monday morning conference call with investors.

Aside from producing a wide variety of branded generic pharmaceuticals, Mylan is known for producing the EpiPen. Upjohn’s brand portfolio includes Zoloft, Xanax and Viagra.

Under the terms of the deal, which is to be structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company.

Pfizer shareholders would own 57 percent of the combined new company, and Mylan shareholders would own 43 percent.

Current Mylan chairman Robert J. Coury will serve as executive chairman of the new company. Upjohn president Michael Goettler will serve as CEO and Rajiv Malik, current Mylan president, will serve as president. 

Ken Parks, currently CFO of Mylan, has agreed to depart the company at closing. Mylan CEO Heather Bresch, who is the 50-year-old daughter of U.S. Senator Joe Manchin of West Virginia, will retire as part of the deal.

Also Monday, Mylan announced an earnings report for the second quarter of 2019. The company reported total revenues of $2.85 billion, which it says is up two percent compared to the same period in the previous year.

Mylan was founded in 1951 as a drug distribution company based in White Sulphur Springs, West Virginia.

More than 3,000 people work at the company’s current Morgantown facilities. The company laid off more than 400 Morgantown employees — or about 15 percent of its operations there — in April 2018.

Mylan has not yet returned requests for comment about the future of its West Virginia operations. 

The as-of-yet named new company, which is expected to be finalized in mid-2020, will be incorporated in Delaware and run operations from Pittsburgh, Shanghai and Hyderabad, India.

 

Gabapentin Contributes to Spike in Overdose Deaths in W. Va.

A West Virginia Board of Pharmacy report says a prescription drug used to treat nerve pain is contributing to a sharp increase of overdose deaths in the state.

The Charleston Gazette-Mail reports the number of fatal overdoses involving gabapentin in West Virginia jumped from three in 2010 to 109 in 2015. The number of 2016 deaths are still being counted.

Pharmacy board administrator Mike Goff, who oversees the state’s drug-monitoring database, says gabapentin is showing up in cocktails of drugs that are linked to overdose deaths. Users seeking a euphoric high mix the drug with opioids or muscle-relaxants and anti-anxiety medications.

“Sometimes, they have prescriptions for all of them,” Goff said.

The increase in deaths has prompted a pharmacy board committee to recommend making gabapentin a controlled substance in West Virginia, enabling the pharmacy board to track prescriptions for the drug, which is sold by Pfizer under the brand name Neurontin.

Goff says currently the volume of gabapentin prescriptions in the state isn’t known.

The gabapentin-related overdose deaths were cited in the pharmacy board’s annual report released last week.

Gabapentin has been approved by the U.S. Food and Drug Administration to treat seizures and pain caused by shingles. It also is used by some veterinarians to treat epilepsy and seizures in dogs and cats.

The U.S. Centers for Disease Control and Prevention has touted gabapentin as a safer alternative to prescription opioids.

Ohio started requiring pharmacies to report sales of gabapentin on Dec. 1.

Exit mobile version